98%
921
2 minutes
20
Background: Disease presentation and progression can vary greatly in heterogeneous diseases, such as COVID-19, with variability in patient outcomes, even within the hospital setting. This variability underscores the need for tailored treatment approaches based on distinct clinical subgroups.
Objectives: This study aimed to identify COVID-19 patient subgroups with unique clinical characteristics using real-world data (RWD) from electronic health records (EHRs) to inform individualized treatment plans.
Materials And Methods: A Factor Analysis of Mixed Data (FAMD)-based agglomerative hierarchical clustering approach was employed to analyze the real-world data, enabling the identification of distinct patient subgroups. Statistical tests evaluated cluster differences, and machine learning models classified the identified subgroups.
Results: Three clusters of COVID-19 in patients with unique clinical characteristics were identified. The analysis revealed significant differences in hospital stay durations and survival rates among the clusters, with more severe clinical features correlating with worse prognoses and machine learning classifiers achieving high accuracy in subgroup identification.
Conclusion: By leveraging RWD and advanced clustering techniques, the study provides insights into the heterogeneity of COVID-19 presentations. The findings support the development of classification models that can inform more individualized and effective treatment plans, improving patient outcomes in the future.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12119499 | PMC |
http://dx.doi.org/10.3389/fpubh.2025.1544904 | DOI Listing |
Curr Opin Infect Dis
September 2025
Infectious Diseases Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna.
Purpose Of Review: Sulbactam-durlobactam (SUL-DUR) is a novel β-lactam/β-lactamase inhibitor combination recently approved for carbapenem-resistant Acinetobacter baumannii (CRAB) infections. This review summarizes current knowledge on the optimal use of SUL-DUR, whether administered alone or in combination with carbapenems, particularly imipenem.
Recent Findings: Data from registrational trial demonstrate that SUL-DUR is an effective and well tolerated treatment option for CRAB severe infections.
JMIR Res Protoc
September 2025
Center for Alcohol & Addiction Studies, School of Public Health, Brown University, Providence, RI, United States.
Background: Digital media frequently contains positive portrayals of alcohol content, which has been shown to be associated with alcohol-related cognitions and behaviors. Because youth are heavy media consumers and have access to unsupervised, repeat viewing of media content on their personal mobile devices, it is critical to understand the frequency of encountering alcohol content in adolescents' daily lives and how adolescents engage with the content.
Objective: This paper outlines the study protocol for examining adolescents' exposure to alcohol-related content in digital media within their natural environments.
Clin Transl Sci
September 2025
Food and Drug Administration, Silver Spring, Maryland, USA.
Since the first decentralized clinical trial (DCT) was conducted in 2011, there has been an increased usage of DCT due to its benefits of patient-centricity and generalizability of findings. This trend was further expedited by the global COVID-19 pandemic. We identified 23 case studies across various therapeutic areas and grouped them into different categories according to their purposes-by necessity, for operational benefits, to address unique research questions, to validate innovative digital endpoints, or to validate decentralization as a clinical research platform.
View Article and Find Full Text PDFOncologist
September 2025
Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, USA.
Background: Belzutifan is a HIF-2ɑ inhibitor approved for the treatment of tumors in von Hippel-Lindau (VHL) syndrome and sporadic metastatic clear cell renal cell carcinoma (spRCC) in the refractory setting. The efficacy and side effects of belzutifan are well-documented from clinical trials, however, real-world data examining the incidence and management of adverse events (AEs) are lacking. Our study aims to describe the AE profiles of belzutifan in spRCC and VHL populations.
View Article and Find Full Text PDFMed Biol Eng Comput
September 2025
Department of Computer Science, Università degli Studi di Bari Aldo Moro, Bari, Italy.
Fetal standard plane detection is essential in prenatal care, enabling accurate assessment of fetal development and early identification of potential anomalies. Despite significant advancements in machine learning (ML) in this domain, its integration into clinical workflows remains limited-primarily due to the lack of standardized, end-to-end operational frameworks. To address this gap, we introduce FetalMLOps, the first comprehensive MLOps framework specifically designed for fetal ultrasound imaging.
View Article and Find Full Text PDF